SCHEMBL2760434

SCHEMBL2760434

CCc1ccc(C#N)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.48
KDM4E B2RXH2 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
BRD4 O60885 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
HPGD P15428 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
AR P10275 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
CHEK1 O14757 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13061999 0.84 RAB9A (0.41) CYP2A6KDM4EL3MBTL1BRD4CYP1A2
SCHEMBL10465159 0.81 L3MBTL1 (0.50) KDM4EL3MBTL1CYP1A2HPGDCYP3A4
SCHEMBL10727406 0.81 CYP2A6 (0.56) CYP2A6ACACB
SCHEMBL6348729 0.80 LOXL2 (0.52) KDM4EBRD4CYP1A2CYP2D6HPGD
SCHEMBL1585201 0.80 ALOX5AP (0.37) CYP2A6BRD4CYP3A4ARRAB9A
SCHEMBL24146512 0.79 GAA (0.38) KDM4EL3MBTL1BRD4ARCHEK1
SCHEMBL2643631 0.79 BRD4 (0.36) BRD4ARRAB9ACHEK1EGLN2
SCHEMBL20448721 0.79 KDM4E (0.42) CYP2A6KDM4EL3MBTL1CYP1A2CYP2D6
SCHEMBL453184 0.79 BRD4 (0.39) BRD4ARCHEK1EGLN2NAMPT
SCHEMBL507109 0.79 AR (0.41) BRD4CYP1A2ARCHEK1EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024050370-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. (US) 2024-03-07 WO disclosed
US-20230373972-A1 PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2023-11-23 US disclosed
WO-2023128282-A1 BIFUNCTIONAL LINKER COMPRISING METAALLYLSILANE AND METHOD FOR PREPARING SAME 한양대학교 에리카산학협력단 2023-07-06 WO disclosed
CN-110325527-B Sulfonamides as inhibitors of extracellular citrate uptake 勃林格殷格翰国际有限公司 2022-08-09 CN disclosed
US-11254686-B1 Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor CORVUS PHARMACEUTICALS, INC. (US) 2022-02-22 US disclosed
US-11034671-B2 Apoptosis signal-regulating kinase inhibitors and uses thereof SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2021-06-15 US disclosed
US-20200392138-A1 PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2020-12-17 US disclosed
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-15 US disclosed
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-06 US disclosed
EP-3551618-B1 SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE BOEHRINGER INGELHEIM INT (DE) 2020-09-16 EP disclosed
US-7273853-B2 6-11 bicyclic ketolide derivatives ENANTA PHARMACEUTICALS, INC. (US) 2007-09-25 US disclosed
EP-1697370-B1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-04-25 EP disclosed
US-7189704-B2 6-11 bicyclic ketolide derivatives ENANTA PHARMACEUTICALS, INC. (US) 2007-03-13 US disclosed
US-7189728-B2 Inhibitors of dipeptidyl peptidase IV FERRING, BV (NL) 2007-03-13 US disclosed
JP-2000226370-A PRODUCTION OF 2-ACYLPYRIDINE DERIVATIVE KURARAY CO LTD 2000-08-15 JP disclosed
US-4923993-A Process for the preparation of 2-pyridinecarboxylic acid derivatives and 1-amino-1,4-dihydropyridine-2-carboxylic acid derivatives CIBA-GEIGY CORPORATION (US) 1990-05-08 US disclosed
EP-0221023-A2 Process for the preparation of pyridine-2-carboxylic-acid derivatives and 1-amino-1,4-dihydropyridine-2-carboxylic-acid derivatives CIBA-GEIGY AG (CH) 1987-05-06 EP disclosed
US-4192880-A ANALGESICS, ANTIINFLAMMATORY AGENTS KANEBO, LTD. (JP) 1980-03-11 US disclosed
US-4188486-A 2-Substituted benzimidazole compounds KANEBO, LTD. (JP) 1980-02-12 US disclosed
US-3959297-A AMMOXIDATION OF 2-METHYL-5-ETHYLPYRIDINE; METAL OXIDE CATALYST SHOWA DENKO KABUSHIKI KAISHA (JA) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 CYP2A6 91/4885KDM4E 1198/4885L3MBTL1 4773/4885
US-11254686-B1 Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor ADORA2A, ADORA2B, ADORA3 CYP2A6 726/4885KDM4E 4408/4885L3MBTL1 4512/4885
US-11034671-B2 Apoptosis signal-regulating kinase inhibitors and uses thereof DAPK1, ATF1, BAD CYP2A6 4487/4885KDM4E 3408/4885L3MBTL1 677/4885
US-20200392138-A1 PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS DDT, ACHE, MNS1 CYP2A6 734/4885KDM4E 4007/4885L3MBTL1 2139/4885
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate CS, GLS, GLS2 CYP2A6 1153/4885KDM4E 2569/4885L3MBTL1 4480/4885
US-20230373972-A1 PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF F7, F11, HABP2 CYP2A6 701/4885KDM4E 1788/4885L3MBTL1 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.